Hepatitis B Trial, Recruiting NCT06160635 Sponsor: Hannover Medical School Condition: Hepatitis B
Back to Hepatitis B

Hepatitis B Trial, Recruiting

NCT06160635
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have tested positive for anti-HDV (an antibody related to the Hepatitis Delta virus)
  • People aged 18 years or older
  • People of any gender (male, female, or diverse)
  • People who have given their informed consent to take part in the study's procedures

Who may not be able to join:

  • People who have tested negative for anti-HDV (the Hepatitis Delta virus antibody)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Markus Cornberg, Hannover Medical School

Phone: +495115326057

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Hannover Medical School
Registry
ClinicalTrials.gov
Start date
22 February 2023
Est. completion
30 September 2026

Where this trial is recruiting

🇩🇪 Germany 🇮🇹 Italy 🇷🇴 Romania 🇸🇪 Sweden

Primary endpoints

Biosample Screening

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov